DM
Deerfield Management Portfolio holdings
AUM
$5.51B
1-Year Est. Return
12.76%
1 Year Est. Return
+12.76%
AUM
$5.04B
AUM Growth
-$213M
(-4%)
Holding
153
Top Buys
| 1 | +$84.8M | |
| 2 | +$84.8M | |
| 3 | +$69.3M | |
| 4 |
Insmed
INSM
|
+$34.9M |
| 5 |
Vera Therapeutics
VERA
|
+$25.2M |
Top Sells
| 1 | +$121M | |
| 2 | +$64.2M | |
| 3 | +$51M | |
| 4 |
Galapagos
GLPG
|
+$38.8M |
| 5 |
BCAX
Bicara Therapeutics
BCAX
|
+$31.3M |
Sector Composition
| 1 | Healthcare | 87.58% |
| 2 | Real Estate | 0.01% |
| 3 | Technology | 0.01% |
| 4 | Consumer Discretionary | 0.01% |
| 5 | Energy | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$6.55B
| $1.28B | 25.19% |
17,991,024
|
|
||
2
Viatris
VTRS
$11.7B
| $209M | 4.13% |
23,991,594
-4,442
|
|
||
3
Neurocrine Biosciences
NBIX
$13.6B
| $165M | 3.25% |
1,489,000
+627,000
|
|
||
4
Centene
CNC
$17.6B
| $162M | 3.2% |
2,671,921
|
|
||
5
Oscar Health
OSCR
$5.31B
| $155M | 3.07% |
11,840,818
+5,818
|
|
||
6
Merus
MRUS
$7.19B
| $134M | 2.64% |
3,173,928
+201,141
|
|
||
7
ARS Pharmaceuticals
SPRY
$1.01B
| $132M | 2.61% |
10,514,657
|
|
||
8
Revolution Medicines
RVMD
$9.24B
| $117M | 2.32% |
3,317,332
+59,000
|
|
||
9
AdaptHealth
AHCO
$1.23B
| $105M | 2.08% |
9,711,410
|
|
||
10
Indivior
INDV
$3.09B
| $101M | 1.99% |
10,567,160
+1,684,000
|
|
||
11
Brookdale Senior Living
BKD
$2.04B
| $97.7M | 1.93% |
15,612,264
|
|
||
12
Alignment Healthcare
ALHC
$3.37B
| $85M | 1.68% |
4,567,473
-2,736,829
|
|
||
13
United Therapeutics
UTHR
$19.4B
| $84.8M | 1.68% |
+275,226
|
|
||
14
Pfizer
PFE
$138B
| $84.8M | 1.67% |
+3,347,296
|
|
||
15
NewAmsterdam Pharma
NAMS
$4.14B
| $84M | 1.66% |
4,103,957
-210,383
|
|
||
16
Catalyst Pharmaceutical
CPRX
$2.51B
| $83M | 1.64% |
3,422,149
+289,138
|
|
||
17
Dynavax Technologies
DVAX
$1.15B
| $67.3M | 1.33% |
5,191,493
-2,330
|
|
||
18
Baxter International
BAX
$11.8B
| $65.8M | 1.3% |
1,923,100
|
|
||
19
Legend Biotech
LEGN
$5.88B
| $59.2M | 1.17% |
1,743,555
+191,837
|
|
||
20
Bio-Rad Laboratories Class A
BIO
$8.39B
| $55.1M | 1.09% |
226,070
+74,426
|
|
||
21
IDEAYA Biosciences
IDYA
$2.42B
| $53.5M | 1.06% |
3,267,551
+531,551
|
|
||
22
Edgewise Therapeutics
EWTX
$1.61B
| $45.7M | 0.9% |
2,078,509
|
|
||
23
Larimar Therapeutics
LRMR
$361M
| $45.6M | 0.9% |
21,231,974
|
|
||
24
Enhabit
EHAB
$406M
| $43.9M | 0.87% |
4,997,746
-13,226
|
|
||
25
Alnylam Pharmaceuticals
ALNY
$63.1B
| $39.2M | 0.77% |
145,000
-191
|
|